 Clinical development of RepliCels skin rejuvenation and tendon regeneration injectables continues to meet milestones on path to commercialization in Japan VANCOUVER, BC ACCESSWIRE July 7, 2021 RepliCel Life Sciences Inc. OTC PINK:REPCFTSXV:RPFSE:P6P2 RepliCel or the Company, a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has submitted its application to Japans Ministry of Health, Labour, and Welfare MHLW for approval to manufacture the Companys RCT-01 cell therapy for chronic tendinopathy and RCS-01 cell therapy for aging and sun-damaged skin for its upcoming clinical studies. With successful phase 1 studies complete, RepliCel is currently preparing for clinical research of its skin rejuvenation RCS-01 and tendon regeneration RCT-01 cell therapies in Japan under the Act for Safety of Regenerative Medicine ASRM which, upon successfully meeting its endpoints, could lead to the commercial launch of the products in Japan. 